China's medical products administrator approved China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary China Resources Zizhu Pharmaceutical's supplementary drug application for diquafosol sodium eye drops.
The drops are indicated for patients with corneal and conjunctival epithelial damage with abnormal production of tears, according to a Tuesday filing with the Shanghai Stock Exchange.
Shares rose 1% during Tuesday's trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments